169 - Regulatory Science of the Future (S12E4)

Welcome to the deep dive. We're cutting straight
to the chase today. Sounds good. We're exploring
the really vital and honestly rapidly changing
field of regulatory science. Yeah. Think of it
maybe as the engine room, the bit that ensures
groundbreaking medical treatments and technologies
are actually safe and effective for all of us.
Absolutely. And what's really key to understand,
I think. is that regulatory science is, well,
it's the practical application of scientific
principles. Right. To the evaluation and regulation
of medical products. It's how we translate discovery
into real health benefits. But always within
that framework of oversight. Exactly, necessary
oversight. And that framework, it's facing some
pretty serious challenges now, isn't it? It really
is. I mean, just look at how complex drug development
has become. That whole journey from an idea in
a lab to your medicine cabinet. the regulatory
demands are just escalating alongside it. Precisely.
Yeah. So our mission today really is to dig into
how regulatory science is stepping up, how it's
adapting. We'll be looking at the shift towards
more adaptable guidelines, these flexible development
pathways, and also the crucial work on global
harmonization. aligning things worldwide. And
this isn't just theory, right? We're going to
pull in some real -world examples from the literature.
Yeah, definitely, including some interesting
cases from OPRD sources to sort of show these
principles in action. Great. So let's get right
to it then. Why are the old ways, the established
ways, of regulating starting to, well... Show
their limits. Yeah, that's the crucial starting
point. Think about these revolutionary fields,
emerging gene therapy, AI diagnostics, nanomedicine.
They're really cutting edge stuff. Exactly. They're
advancing incredibly fast. And their basic mechanisms
are often just fundamentally different from traditional
drugs. So the challenge is that our existing
regulatory structures, they were mostly built
on experience with conventional treatments. They
might just lack the inherent agility needed for
these new approaches. So it's about making sure
regulation isn't a bottleneck, stopping real
progress, but still keeping things safe. That's
the balance, precisely. Fostering innovation
while safeguarding patients. If regulations are
too rigid, too slow. Promising therapies get
delayed. Exactly. And that ultimately hurts patients.
So it really brings up a critical question. How
do we build a system that's, you know, scientifically
robust and responsive to this rapid change. Which
leads us straight to adaptive guidelines and
these flexible pathways. Let's start with adaptive
guidelines. What does that actually mean? Okay,
think of adaptive guidelines as moving away from
a static rule book. You know, one set of rules
that never changes. Right. Towards something
more dynamic. A framework that's intentionally
designed to be adjusted, refined, as we get more
data. As we get real -world experience with a
new product. So learning continues after it's
on the market. The basic idea is just that, yeah,
our understanding evolves. and the regulations
need to reflect that evolving knowledge. That
makes a lot of sense. It's like acknowledging
the learning curve. Now, how do flexible pathways
fit in? Things like accelerated approval or breakthrough
therapy designation. We've touched on these before.
Yeah, these are excellent examples of putting
that flexibility into practice. Accelerated approval,
for instance. It allows earlier approval for
drugs that treat serious conditions, especially
where there's an unmet need. And it's often based
on what's called a surrogate endpoint. A marker,
right, something that suggests a benefit. Exactly.
A marker that's reasonably likely to predict
a real clinical benefit. It acknowledges the
urgency, you know, getting potentially life -saving
treatments out sooner. But as we discussed back
then, relying on those surrogate endpoints means
you need confirmation later on, don't you? Absolutely.
That's why post -marketing studies are, well,
they're non -negotiable. They're required with
accelerated approval. To prove the benefit for
real. Precisely. These studies have to definitively
show the predicted clinical benefit. And if they
don't, the approval can actually be withdrawn.
Okay. It's a system of, you could say, conditional
approval. It prioritizes speed but keeps that
commitment to proving long -term efficacy. And
breakthrough therapy. That also speeds things
up, but it's based on different criteria. Correct.
Breakthrough designation is for when preliminary
clinical evidence suggests a substantial improvement
over what's already available for serious conditions.
So a big leap forward. Potentially, yes. The
aim there is to speed up both the development
and the review with more intensive guidance from
the regulators all along the way. It's about
spotting those therapies with exceptional early
promise and giving them a faster route. OK, so
we're seeing this clear move towards more adaptability,
more speed in specific, justified cases. How
does this adaptive thinking apply to some of
the really frontier technologies, like AI -based
medical devices? Oh, this is a fascinating area,
and one where the traditional model really gets,
well, disrupted. Medical devices are typically
classified by risk. Yeah, different classes based
on potential harm. Exactly. But what's really
interesting with AI is that an algorithm... Its
behavior can actually change over time. It learns.
It's not static. Right. And that doesn't fit
neatly into risk categories that were defined
just once at the time of approval. So the initial
risk assessment might not hold true. The AI could
become, I don't know, more or less risky as it
learns more. That's the core issue. Regulatory
frameworks like the EU's MDR, they lay out general
requirements. Risk management, clinical evaluation,
sure. Manufacturers still need the CE mark, that
declaration of conformity. Absolutely. But the
challenge is how do you continuously monitor
and regulate a device whose main function is
dynamic? It's changing. How do you ensure ongoing
safety for something that's essentially learning
and evolving. That's the million -dollar question
regulators are grappling with right now. It's
really complex. Okay, let's switch gears slightly.
What about a different kind of innovation, continuous
manufacturing and pharma? We talked about scale
-up challenges before. How does regulation adapt
here? Right, continuous manufacturing. Producing
drugs in an uninterrupted flow, not in separate
batches. It offers huge advantages. Efficiency,
quality control. Sounds much better. It can be,
but it also demands a shift in regulatory thinking.
Traditional regs often focus on testing individual
batches, right, and product testing. Yeah, test
a sample from the batch. With continuous manufacturing,
the focus really needs to move towards real -time
monitoring and control. of the entire process.
So instead of just checking the end result, you
need confidence in the whole ongoing process,
the monitoring systems. Exactly. You need sophisticated
process analytical technology, or PIT, constantly
monitoring critical quality attributes. So regulators
are adapting. They're focusing more on the reliability,
the consistency of the continuous process itself.
Not just the final pill. Not just the final pill.
And this really highlights why understanding
critical process parameters is so vital, like
that gelling issue we discussed from the OPR
&D paper. During scale -up, yeah. That understanding
becomes even more critical in a continuous system
where things are constantly flowing. One small
deviation could ripple through. OK, that makes
sense. Another area pushing boundaries seems
to be personalized medicine. targeted therapies.
Absolutely. Therapies designed for specific patient
subgroups based on their genes or biomarkers.
They're becoming much more common. And this needs
a more refined regulatory strategy. Traditional
clinical trials often use broad patient populations,
you know. Trying to see if it works generally.
Kind of. But personalized medicine often means
smaller, much more targeted trials, very specific
groups. So the way we gather the evidence has
to change too. It has to evolve. We're seeing
more emphasis now on things like pharmacodynamic
endpoints, biomarkers, even changes in gene expression
in toxicology studies. Remember we touched on
selecting animal models for specific cancer pathways.
Yeah, finding the right model. It's related.
Regulators are adapting. giving more weight to
these targeted endpoints, and also to companion
diagnostics, the tests used to identify which
patients are likely to benefit. So you test the
patient first, then give the target a drug if
it's a match. That's the idea. But it also brings
up an important point. How do we make sure there's
equitable access to therapies that are so narrowly
targeted? That's another challenge. These are
such varied complex challenges. It really feels
like we need a globally coordinated approach.
Is that where harmonization comes in? Precisely.
International collaboration, harmonizing regulatory
standards. It's vital, especially for getting
innovative therapies developed and available
worldwide. So organizations like ICH, the International
Council for Harmonization. Yes, they play a central
role developing harmonized guidelines that regulatory
authorities like the FDA in the US or the EMA
in Europe can adopt. So they're trying to get
on the same page, basically, the FDA and EMA
and others. That's the goal. Harmonization can
really streamline drug development. less duplication
of effort, faster availability of new medicines
across different regions. In that sense. Now,
achieving complete harmonization, that's tough.
There are different legal systems, different
procedures. Sure. But the benefits, especially
for efficiency and patient access, make it a
really critical goal. Okay. Let's try and ground
this a bit more with some of those real -world
examples. You mentioned OPRND literature. Yes.
So there's a 2021 publication, OPRND 2021b. It
talks about using HFFIP. It's a specific type
of alcohol. To significantly improve both the
yield and the selectivity in a key chemical reaction
for making a drug. Now, why does this matter
for regulation? Better chemistry means? It means
potentially more efficient, more cost -effective
manufacturing. And that ultimately can benefit
patients by making medicines potentially more
accessible, maybe cheaper. It shows how optimizing
the basic chemistry matters. It's about making
sure the process itself is solid, reliable. Exactly.
And there was another paper, OPR &D 2021C, on
developing a manufacturing route for a drug called
Rovaphoveridilafenamide. Right. What was the
regulatory angle there? That paper really emphasizes
the huge amount of process development work needed
to get a commercially viable route. A big focus
was on reducing something called process mass
intensity. Less waste. Essentially, yes. minimizing
waste during manufacturing, and also enhancing
the robustness, the reliability of the process.
And crucially, they tackled impurity control.
Getting rid of unwanted stuff. Exactly. Developing
sophisticated crystallization techniques to remove
potentially harmful byproducts. It shows how
regulatory science looks beyond just the final
product. It scrutinizes the whole manufacturing
journey. Safety, efficiency, purity. And as we
know, that journey isn't always smooth. We talked
about scale -up issues before, like that gelling
problem referenced from an older ORD paper in
our Season 6 discussion. Right. That gelling
problem during scale -up, it just perfectly highlights
the critical need to really understand and control
your process parameters. What works in the lab
doesn't always work in the factory. Not always,
no. What's smooth on a small scale can get really
messy when you scale it up for industrial production.
Regulatory science puts a huge emphasis on identifying
and controlling those critical parameters. You
have to prevent unexpected issues that could
compromise quality. Makes sense. And similarly,
remember the difficulties with standard alkaline
hydrolysis, leading to unwanted side reactions.
Yeah, that causes problems too. It just underscores
again how important that deep process understanding
and optimization is, especially for meeting those
really stringent regulatory purity requirements.
You have to get it right. So it really is this
continuous cycle, isn't it? Learning, adapting,
refining, both in the science lab and within
the regulatory rules themselves. Looking ahead
then, what are the big ongoing challenges and
maybe the emerging trends in regulatory science?
Well, a persistent challenge is always that balance.
Fostering innovation versus ensuring safety.
It's inherent in the job. The core tension. Exactly.
And as technologies get more complex, evaluating
them gets more complex too. Yeah. We also need
to keep pushing for global harmonization while
still respecting necessary regional differences.
That's tricky. And looking forward. What's coming?
I think we'll definitely see more integration
of real world data. Information gathered from
actual patient use outside of trial. Data from
the real world, not just the lab. Right. AI itself
could also become a powerful tool for regulators,
helping analyze these massive data sets. I expect
we'll continue evolving towards more personalized
risk benefit assessments, tailoring the regulatory
approach to the specifics of the therapy and
the patient population it's intended for. It
really hammers home that regulatory science isn't
static. It's this constantly evolving field,
wholly essential for navigating medical progress.
Absolutely. It's the framework, the crucial framework,
that allows scientific breakthroughs to actually
translate into tangible benefits for you, the
patient, safely and effectively. So to wrap up
our deep dive today. We've seen that regulatory
science isn't some fixed rule book. It's dynamic.
It's adaptive. It's vital for enabling innovation
while rigorously protecting public health. And
that evolution through adaptive guidelines, flexible
pathways, harmonization, it's absolutely essential
to keep pace with the incredible speed of science
and technology. And it's important for you, the
listener, to remember this isn't just some bureaucratic
process happening behind closed doors. It directly
impacts the treatments that become available
to you. Could we agree more? So on that note,
here's a final thought for you to ponder. How
can a more agile, more globally aligned regulatory
system for these cutting edge innovations best
serve patients and the whole health care system?
What role can everyone play, researchers, industry,
regulators, even patients like you in shaping
that future? We definitely encourage you to explore
the sources we've touched on and keep digging
into this fascinating intersection of science,
tech and regulation. Thanks for joining us on
this deep dive.